Retail price of 51 formulations fixed by NPPA
Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of the 51 formulations including those used to treat type 2 diabetes, bacterial infections, and others.
This came in line with the decision of the 114th Authority meeting dated 19.06.2023, where the authority discussed the new drug applications for price fixation under para 5 and 15 of DPCO 2013.
These include Skymap Healthcare & Healing Pharma's Ciprofloxacin & Dexamethasone Eye Drops, Cris Pharma& Mankind Prime Lab's Paracetamol, Phenylephrine and Chlorpheniramine Drops, Akums Drugs & Eris Life science's Paroxetine Controlled release & Clonazepam Capsules.
For more details, check out the link given below:
NPPA Fixes Retail Price Of 51 Formulations, Details
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.